Thoracic Cancer Centre, Pulmonology Unit, University Hospital of Pisa, Pisa, Italy; Department of Pediatric Oncology and Hematology, Anna Meyer Children's University Hospital, Florence, Italy.
Medical Oncology Unit, IRCCS Neuromed, Pozzilli, Italy; Medical Oncology Unit, Italian Neuro-Traumatology Institute, Grottaferrata, Italy.
Crit Rev Oncol Hematol. 2017 Nov;119:66-74. doi: 10.1016/j.critrevonc.2017.08.005. Epub 2017 Aug 25.
Cancer-related bone pain is a frequent and important key problem for metastatic patients that may reduce quality of life, with related limitations in daily activities and morbidity. Often traditional approach to pain may fail given the complex pathophysiology of this phenomenon.
The aim of this review is to describe promising therapies for cancer-related bone pain, from the pathophysiology to the clinical trials currently ongoing. Moreover, any new evidence for better approach to cancer-related bone pain with the traditional drugs is also considered.
In clinical practice opioids remain the most important pharmacologic treatment for severe pain related to bone cancer. Regard developing drugs, anti-NGF and anti-TrkA are the most investigated new drug in this setting, but a future role in clinical practice is still uncertain.
癌症相关骨痛是转移性患者常见且重要的关键问题，可能会降低生活质量，并导致日常活动受限和发病率增加。鉴于这种现象的复杂病理生理学，通常传统的疼痛处理方法可能会失败。
本综述旨在描述癌症相关骨痛的有前途的治疗方法，从病理生理学到目前正在进行的临床试验。此外，还考虑了任何用于改善癌症相关骨痛的传统药物的新证据。
在临床实践中，阿片类药物仍然是治疗骨癌相关严重疼痛的最重要的药物治疗方法。关于开发药物，抗神经生长因子（anti-NGF）和抗原肌球蛋白受体激酶 A（anti-TrkA）是该领域研究最多的新药，但在临床实践中的未来作用仍不确定。
